Abstract Number: 1242 • 2014 ACR/ARHP Annual Meeting
Switching Biologic Agents in Refractory Adult-Onset Still’s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center
Background/Purpose No data is available on the long-term clinical outcome of Adult-Onset Still's Disease (AOSD) patients treated with biological drugs, nor on the efficacy and…Abstract Number: 2494 • 2014 ACR/ARHP Annual Meeting
Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare
Background/Purpose: Few rheumatoid arthritis (RA) patients are managed successfully with a single disease modifying anti-rheumatic drug (DMARD). This investigation determined the prevalence and clinical…Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…Abstract Number: 2419 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review
Background/Purpose: In the last decade, biologic medications have transformed the management of RA. The effectiveness of these medications has been reported in numerous randomized controlled…Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…Abstract Number: 2388 • 2014 ACR/ARHP Annual Meeting
DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality
Background/Purpose Previous studies have suggested that disease modifying anti-rheumatic drugs (DMARDs) may reduce cardiovascular risk among patients with rheumatoid arthritis (RA). This analysis examined whether…Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…Abstract Number: 2368 • 2014 ACR/ARHP Annual Meeting
Impact of Physicians’ Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis
Background/Purpose We have previously shown that in early rheumatoid arthritis (RA) remission targeted, intensive combination treatment, regardless of initial infliximab, results in remission in most…Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…Abstract Number: 2205 • 2014 ACR/ARHP Annual Meeting
Management of Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease
Background/Purpose: In the Southwestern United States, coccidioidomycosis (valley fever) is an endemic fungal infection which typically causes a self-limited pulmonary illness. Immunosuppressed patients, including those…Abstract Number: 496 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study
Background/Purpose Additional administration of low-dose tacrolimus (LD-TAC) at 0.5–1.0 mg daily was reported to be quite effective for rheumatoid arthritis (RA) patients with inadequate response…Abstract Number: 2646 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis: Analysis Based On The TEAR Trial
Background/Purpose: The long-term cost-effectiveness of triple therapy (methotrexate [MTX], sulfasalazine [SSZ], hydroxychloroquine [HCQ]) disease modifying anti-rheumatic drugs (DMARDs) compared to a combination of MTX and…Abstract Number: 1040 • 2013 ACR/ARHP Annual Meeting
Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients
Background/Purpose: Inflammation may contribute to diabetes risk, and some studies indicate that certain DMARDs might be associated with a reduced risk of diabetes. Most studies…Abstract Number: L14 • 2013 ACR/ARHP Annual Meeting
For Remission Induction with Glucocorticoid Bridging, Methotrexate Monotherapy Is As Effective As a Combination with Other Dmards, with Fewer Reported Side Effects: 4 Month Primary Outcome of Carera, a Randomized Induction Strategy and Treat to Target Trial in Early RA
Background/Purpose: Intensive combination therapy with glucocorticoids (GCs) is the most favorable treatment to benefit from the window of opportunity in early Rheumatoid Arthritis (eRA) but…Abstract Number: 2483 • 2013 ACR/ARHP Annual Meeting
Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry
Background/Purpose: Hand bone loss is an early feature in both RA and PsA, but there is less data available on periarticular bone gain, in particular…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 24
- Next Page »